ArticleCancer medicine2026
Analysis of Treatment Patterns for Mucosal Melanoma Using Real-World Data in the SEER-Medicare-Linked Database.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal melanoma (MM) is a rare, aggressive disease, often diagnosed late, and associated with poor survival. Surgical resection is the main potential curative option, but anatomical complexity limits feasibility, and real-world evidence on treatment patterns remains scarce. This study aimed to describe treatment patterns across lines of therapy among patients diagnosed with MM in the US Surveillance, Epidemiology, and End Results Program (SEER)-Medicare-linked population.
methodsA retrospective analysis was conducted using SEER-Medicare-linked data from January 2014 through December 2021, with follow-up through December 2023. Patients aged ≥ 65 years with MM were identified using SEER histology and International Classification of Diseases for Oncology, Third Edition (ICD-O-3) topography codes. Treatment patterns were evaluated by categorizing patients into surgical and nonsurgical cohorts and assessing systemic therapy use across lines of treatment. Descriptive statistics summarized patient demographics, tumor characteristics, and treatment modalities.
resultsAmong 1362 MM patients (median age, 76 years; 57.6% female), 41.3% underwent surgery. Among surgical patients, 36.2% received adjuvant systemic therapy, with PD-1/PD-L1-based regimens accounting for 51.5% overall; use varied by primary site and stage, with higher uptake in rectal/anal and nasal cavity melanoma and in regional-stage disease. In the nonsurgical cohort, 63.3% received systemic therapy as first-line treatment, with higher use in rectal/anal melanoma and distant-stage disease. PD-1/PD-L1-based regimens predominated (66.6%), with monotherapy used in 55.5% and combination therapy more frequently selected in higher-risk subsites and advanced-stage disease.
conclusionCombination regimens were more common among patients who did not undergo surgery and in certain high-risk subsites, reflecting heterogeneity in treatment intensity across anatomical locations and stages. This pattern likely reflects more advanced or complex disease presentations in these groups, underscoring the need for intensified therapy despite the higher risk of toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.